Paid Macular Degeneration Clinical Trials
AMD clinical trials recruiting. Access new treatments for wet and dry macular degeneration. Compensation up to $3,500. Studies with retina specialists.
Compensation
$1,800 - $3,500
Duration
52-104 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 50-90 years
- Diagnosis of age-related macular degeneration (wet or dry)
- Best-corrected visual acuity meeting study criteria
- Adequate media clarity for retinal imaging
- Willing to comply with frequent study visits
- Specific lesion characteristics on imaging (study-dependent)
Who May Not Qualify
- Active eye infection or inflammation
- Prior vitrectomy in study eye
- Uncontrolled glaucoma
- Diabetic retinopathy in study eye
- Recent eye surgery (within specified timeframe)
Frequently Asked Questions
What AMD treatments are being studied?
+
For wet AMD, studies include longer-acting anti-VEGF treatments requiring fewer injections, gene therapy, and combination approaches. For dry AMD, studies investigate complement inhibitors, neuroprotective agents, and emerging treatments.
How often are eye injections given?
+
For wet AMD studies, injection frequency varies from monthly to quarterly depending on the treatment. Some studies compare fixed vs. as-needed dosing schedules.
What eye tests are performed?
+
Studies include visual acuity testing, OCT imaging, fundus photography, and sometimes fluorescein angiography. These non-invasive tests assess retinal structure and function.
Are there studies for early AMD or prevention?
+
Yes, studies exist for intermediate AMD (geographic atrophy/dry AMD) aiming to slow progression. These typically do not involve injections and focus on oral medications or supplements.